PMID- 27210070
OWN - NLM
STAT- MEDLINE
DCOM- 20170303
LR  - 20170303
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 63
IP  - 7
DP  - 2016 Jul 30
TI  - Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or 
      recurred and progressive differentiated thyroid carcinoma [Review].
PG  - 597-602
LID - 10.1507/endocrj.EJ16-0064 [doi]
AB  - Differentiated thyroid carcinoma (DTC) is generally indolent in nature and, even 
      though it metastasizes to distant organs, the prognosis is normally excellent. In 
      contrast, the overall survival (OS) of patients with radioactive iodine 
      (RAI)-refractory and progressive metastases is dire, because no effective 
      therapies have been available to control the metastatic lesions. However, 
      recently, administration of tyrosine-kinase inhibitors (TKIs) has become a new 
      line of therapy for RAI-refractory and progressive metastases. Previous studies 
      have reported significant improvement regarding the progression-free survival 
      rates of patients with metastatic lesions. However, TKIs cause various severe 
      adverse events (AEs) that damage patients' quality of life and can even be 
      life-threatening. Additionally, metastatic lesions may progress significantly 
      after stopping TKI therapy. Therefore, it is difficult to determine who is a 
      candidate for TKI therapy, as well as how and when physicians start and stop the 
      therapy. The present review, created by Committee of pharmacological therapy for 
      thyroid cancer of the Japanese Society of Thyroid Surgery (JSTS) and the Japan 
      Association of Endocrine Surgeons (JAES) describes how to appropriately use TKIs 
      by describing what we do and do not know about treatment using TKIs.
FAU - Ito, Yasuhiro
AU  - Ito Y
AD  - Committee of Pharmacological Therapy for Thyroid Cancer of Japan Association of 
      Endocrine Surgery (JAES) and Japanese Society of Thyroid Surgery (JSTS), Japan.
FAU - Suzuki, Shinichi
AU  - Suzuki S
FAU - Ito, Ken-Ichi
AU  - Ito K
FAU - Imai, Tsuneo
AU  - Imai T
FAU - Okamoto, Takahiro
AU  - Okamoto T
FAU - Kitano, Hiroya
AU  - Kitano H
FAU - Sugitani, Iwao
AU  - Sugitani I
FAU - Sugino, Kiminori
AU  - Sugino K
FAU - Tsutsui, Hidemitsu
AU  - Tsutsui H
FAU - Hara, Hisato
AU  - Hara H
FAU - Yoshida, Akira
AU  - Yoshida A
FAU - Shimizu, Kazuo
AU  - Shimizu K
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160520
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma/*drug therapy/pathology/radiotherapy
MH  - Chemotherapy, Adjuvant
MH  - Disease Progression
MH  - Humans
MH  - Iodine Radioisotopes/*therapeutic use
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Thyroid Neoplasms/*drug therapy/pathology/radiotherapy
MH  - Treatment Failure
EDAT- 2016/05/24 06:00
MHDA- 2017/03/04 06:00
CRDT- 2016/05/24 06:00
PHST- 2016/05/24 06:00 [entrez]
PHST- 2016/05/24 06:00 [pubmed]
PHST- 2017/03/04 06:00 [medline]
AID - 10.1507/endocrj.EJ16-0064 [doi]
PST - ppublish
SO  - Endocr J. 2016 Jul 30;63(7):597-602. doi: 10.1507/endocrj.EJ16-0064. Epub 2016 
      May 20.